Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study Evaluation the Use of Serial Plasma Next-generation Sequencing (NGS) as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation

NCT06146920 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT06146920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06146920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study Evaluation the Use of Serial Plasma Next-generation Sequencing (NGS) as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
Lead sponsor
Massachusetts General Hospital
Phase
Not applicable
Overall status
Active, not recruiting
Start date
January 10, 2024
Completion date
November 30, 2028
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, non-small cell lung cancer